Posttransplant Diabetes Mellitus, Posttransplant Impaired Glucose Tolerance, Renal Transplant Recipients
Conditions
Keywords
Nateglinide, Renal, Kidney, Transplantation, Diabets, Glucose
Brief summary
The objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. Primarily will the change in glucose tolerance and acute insuline responce be addressed.
Interventions
DRUGNateglinide
Sponsors
University of Oslo School of Pharmacy
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Reduced glucose tolerance (fasting glucose \< 6.1 mmol/L AND 2 hour glucose between 6.7 and 9.9 mmol/L) or posttransplant diabetes mellitus (fasting glucose \> 6.1 mmol/L OR 2 hour glucose between \>= 10.0 mmol/L) * Stable patients fgollowing renal transplantation, less than 25% variation in serum creatinine last week and serum creatinine \< 200 micromol/L
Exclusion criteria
* Patients with indulin dependent diabetes mellitus before or after transplantation * Planned change in daily prednisolone dose during the study period * Haemoglobin \< 8g/dL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucose tolerance | — |
| Insuline release | — |
Secondary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate | — |
| HbA1C | — |
| Glucose oxidation | — |
| Plasma nitric oxide | — |
| Plasma endothelin-1 | — |
| Fasting glucose | — |
| Postprandial hyperlipidemia | — |
Countries
Norway
Outcome results
None listed